Sangamo Therapeutics Inc (SGMO) VP Sells $308850.00 in Stock

Adjust Comment Print

Exelixis, Inc. (EXEL) stock is now trading 13.04% away from its average-price of 200 days while it maintained a distance of 1.10% from its 50 Days Moving Average and -2.47% compared with the 20 Day Moving Average. - Clos (NASDAQ:FUND) has risen 25.12% since February 8, 2017 and is uptrending.

Recent insider trends for Sangamo Therapeutics, Inc.

Fic Capital Inc decreased its stake in Sangamo (SGMO) by 5.3% based on its latest 2017Q3 regulatory filing with the SEC. It was reported on Feb, 8 by The company's 3-months average volume stands at 1.47 million. The stock decreased 2.35% or $1.8 during the last trading session, reaching $74.65. At one point in the past year, the shares traded as low as $26.26 but has recovered 117.71% since then. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 7, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.The move comes after 7 months negative chart setup for the $1.80B company.

Short interest, or the number of a stock's tradable shares now being shorted, is another metric investors use to get a pulse on sentiment. Sarepta Therapeutics, given 6 buy-equivalent recommendations, 0 sells and 1 holds. Fic Capital Inc who had been investing in Sangamo for a number of months, seems to be less bullish one the $1.83B market cap company. 27 funds opened positions while 50 raised stakes. 132,741 were accumulated by California State Teachers Retirement Sys. Frontier Mngmt Limited Liability Corp reported 487,788 shares or 0.05% of all its holdings. Advisory Ser Networks Ltd Llc holds 0% or 300 shares in its portfolio. Finally, Principal Financial Group Inc. grew its holdings in Sangamo Therapeutics by 6.8% during the 2nd quarter. Bancorp Of Montreal Can holds 877 shares or 0% of its portfolio. Altrinsic Advsrs Ltd Co has 0.31% invested in Sangamo Therapeutics, Inc. Following the completion of the sale, the director now owns 5,000 shares of the company's stock, valued at $73,350. The total dollar value of all 91.19 million outstanding shares is 2.02 billion. Invesco Limited invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. Dimensional Fund Advsrs Ltd Partnership holds 0% or 233,752 shares in its portfolio. 30,100 are held by Strs Ohio. Nationwide Fund Advsr owns 0% invested in Sangamo Therapeutics, Inc. The hedge fund held 188,260 shares of the energy company at the end of 2017Q3, valued at $5.24M, down from 236,160 at the end of the previous reported quarter. Wedbush maintained Sangamo Therapeutics, Inc.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, November 9th.

Troubles mount for Manikarnika as Brahmin groups threaten its release
Rani Laxmibai was a freedom fighter and one of the most respected leaders our country has seen. This shows that we are making the film with sheer honesty and purity.

On average, analysts expect that Sangamo Therapeutics will report full year sales of $11.28 million for the current fiscal year, with estimates ranging from $34.00 million to $38.20 million. (NASDAQ:SGMO) was sold by Herberts Curt A. III. On Wednesday, September 20 RINGO WILLIAM R sold $445,597 worth of Sangamo Therapeutics, Inc. It dived, as 23 investors sold KEX shares while 67 reduced holdings.

This company shares (SGMO) so far managed to recover 463.38% since collapsing to its 52-week low. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth. Rating Scale; where 1.0 rating mean Strong Buy, 2.0 rating signifies Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Therefore 70% are positive. The perception is that the lower the P/E, the higher will be the value of the stock. This metric reflects the average amount a stock's price has differed from the mean over a period of time. (NASDAQ:SGMO) to report $-0.18 EPS on February, 27.They anticipate $0.04 EPS change or 28.57% from last quarter's $-0.14 EPS. Piper Jaffray maintained the stock with "Buy" rating in Wednesday, January 3 report. The firm earned "Neutral" rating on Wednesday, October 19 by PiperJaffray. Wedbush maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned "Overweight" rating by PiperJaffray on Wednesday, November 15. The rating was maintained by Jefferies on Tuesday, September 12 with "Buy". (NASDAQ:SGMO) on Wednesday, September 2 with "Buy" rating. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The companyÂ's proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Among 24 analysts covering Cavium Networks Inc. (NYSE:C), 19 have Buy rating, 3 Sell and 18 Hold. Therefore 42% are positive. Kirby Corporation (NYSE:KEX) has declined 0.86% since February 8, 2017 and is downtrending. The firm has "Hold" rating given on Thursday, August 6 by Vetr. The firm has "Sell" rating given on Tuesday, September 8 by Zacks. The stock has "Buy" rating by Jefferies on Friday, October 13. That's right - they think these 10 stocks are even better buys. The rating was reinitiated by UBS with "Sell" on Wednesday, January 11. Credit Suisse Ag owns 21,572 shares or 0% of their U.S. portfolio. Jefferies downgraded Citigroup Inc. The rating was maintained by Morgan Stanley with "Overweight" on Thursday, November 2. Oppenheimer maintained Citigroup Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.